J. Stark Thompson, PhD

J. Stark Thompson, PhD
Non-Executive Chairman

Dr. Thompson has nearly five decades of corporate leadership and business management experience, dating back to when he joined the DuPont Company in 1967. From 1988 until 2000, Dr. Thompson served as President, CEO and board member of Life Technologies, Inc. Dr. Thompson has served on and led various boards of directors at companies including Gene Logic, Inc. and Luminex Corporation. He received his BS from Muskingum University, and his MSc and PhD in physiological chemistry from Ohio State University.

Doug Doerfler

Doug Doerfler
President and Chief Executive Officer

Mr. Doerfler has 35+ years of vast experience in biotechnology product and company development, commercialisation and international financing. He was a founder of MaxCyte in July 1998. Previously, he was President, CEO and a Director of Immunicon Corporation. He also held various executive positions with Life Technologies, Inc. (now Thermo Fisher).

Mr. Doerfler is an active Life Sciences industry advocate, serving as Chair Emeritus of the Maryland Tech Council and on the executive committee of the Biotechnology Innovation Organization. He received his BS in finance from the University of Baltimore School of Business, and holds an Industrial Relations certificate.

Yasir Al-Wakeel

Yasir Al-Wakeel, BM BCh
Non-Executive Director

Dr. Al-Wakeel currently serves as CFO and Head of Corporate Development for Kronos Bio, where he was instrumental in the company’s $288 million IPO. He previously served as CFO and Strategy Officer at Neon Therapeutics (now BioNTech) and was CFO and Head of Corporate Development at Merrimack Pharmaceuticals (now Ipsen). Prior to those roles, Dr. Al-Wakeel served in senior roles in equity research and corporate finance at Credit Suisse focused on the biotechnology sector. Dr. Al-Wakeel began his career as a practicing physician, holding both clinical and academic medical posts in the United Kingdom. He holds a BM BCh from Oxford University and an MA in theology from Cambridge University.

Will Brooke

Will Brooke
Non-Executive Director

Mr. Brooke is a Limited Partner of Harbert Management Corporation (“HMC”), which he co-founded in 1993. He has been advising and investing in early-stage and growth companies for 20+ years, and served on the boards of numerous pharmaceutical and medical equipment companies. He presently serves as a board member of KPX, LLC, an ESG advisory firm. Mr. Brooke has previously served as HMC’s General Counsel, its Chief Operating Officer, and as Chairman of its Real Estate Services subsidiary. Prior to joining HMC, Mr. Brooke practised law for a decade. He holds a JD and a BS, both from the University of Alabama.

Richard Douglas

Richard Douglas, PhD
Non-Executive Director

Dr. Douglas formerly served as the SVP of Corporate Development and Corporate Officer at Genzyme Corporation from 1989 until 2011. There, he led numerous acquisitions, licences, financings, joint ventures, and strategic alliances. He had previously held scientific and corporate development roles at Integrated Genetics. He is currently an adviser to RedSky Partners, Chairman of the Board of Aldeyra Therapeutics, and a director of Novavax Inc., and chairman of the National Advisory Board of the Office of Technology Transfer at the University of Michigan. Dr. Douglas received a PhD in Biochemistry from the University of California, Berkeley, and was a Post-Doctoral Fellow at California Institute of Technology in Leroy Hood’s laboratory. He has a BS degree in Chemistry from the University of Michigan.

Stan Erck

Stan Erck
Non-Executive Director

Mr. Erck is President and CEO, and director of Novavax Corporation. His 35 years of management experience in the healthcare and biotechnology industry include positions at Baxter International and Integrated Genetics, and as CEO and Director of Procept and Iomai. In addition to successfully negotiating major alliances with biopharmaceutical companies and bringing products into clinical trials, he has managed the process of developing companies from private funding through to IPO. Mr. Erck received his BS from the University of Illinois and an MBA from the University of Chicago.

Rekha Hemrajani

Rekha Hemrajani
Non-Executive Director

Ms. Hemrajani is a senior executive with more than 20 years of biopharmaceutical industry experience. She currently serves as CEO (part time) and director of Jiya Acquisition Corp, where she led the $100 million initial public offering. Ms. Hemrajani has held senior management positions at numerous listed biopharmaceutical companies, including President, CEO and Director of Aravive, Inc., CFO and COO of Arcus Biosciences, Inc., and COO of RAPT Therapeutics (formerly FLX Bio), Inc. Ms. Hemrajani received a MBA from Northwestern University and a BS in economics and computer science from the University of Michigan. Ms. Hemrajani also serves as non-executive director of ALX Oncology Holdings, Inc.

John Johnston

John Johnston
Non-Executive Director

After a career spanning 30+ years in the city of London, Mr. Johnston held non-executive positions in a wide range of industries including pharmaceutical, medical, energy and international hospitality. Previously, he was Managing Director of Institutional Sales at Nomura Code and Director of Sales and Trading at Seymour Pierce. Prior to this, he spent 26 years as a fund manager, managing a variety of asset classes including UK general equities, Japanese equities and technology funds. The last 15 years of his fund management career were focused almost exclusively on small cap and AIM stocks.

Art Mandell

Art Mandell
Non-Executive Director

Mr. Mandell is a senior healthcare executive with 30+ years of experience leading companies, executing large corporate and business development deals, and developing and commercializing products. He served as President and COO of Prestwick Pharmaceuticals, Inc. Prior to Prestwick, Mr. Mandell was President, CEO, and a director of Cellective Therapeutics, Inc. (acquired by Astra Zeneca/MedImmune). Before Cellective, Mr. Mandell served as President, CEO, and director of Stemron Corporation, and as SVP and CBO of Human Genome Sciences, Inc. Mr. Mandell began his healthcare career at Syntex Pharmaceutical Corporation.

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Sign Up